With the right team, the right knowledge and the right tools, we deliver what you need when you need it. The result: a shorter, simpler and more cost-effective path to your goal.
NAMSA’s commitment to the safe and effective development of your device extends across our entire organization and on through our relationships and partnerships within the industry. The strategic partners we have chosen share our unbridled enthusiasm, extensive expertise, professionalism and commitment to the development of your device.
Our partners are carefully selected for not only their expertise and experience, but also our shared values and resolve to lead the industry forward in advancements and efficiencies.
Fortuna Clinical (www.fortunaclinical.com) is a US based company dedicated to supporting cardiovascular device clinical trials in the US and Europe. It provides services for all stages of device development including regulatory, clinical and medical support and post market approval services. It was founded by Jan Skowronski, MD, MBA, who has been a leading US endovascular cardiologist. Fortuna Clinical focuses on all cardiovascular studies including coronary, structural heart, peripheral arterial disease, endografts and venous disease devices.
Blanchard & Associates (www.blanchardyasociados.com) is a clinical research organization (CRO) founded by professionals with over 20 years of experience in Clinical Research, in operations for more than 7 years, and has executed numerous clinical studies for clients throughout South America.